Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 213

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 213
---
 currently exercisable or exercisable within 60 days of the       
 date of this Annual Report, exercisable at an exercise price of CAD$504.0 and expiring in February 2032.                                |

Record Holders As of December 3, 2025, there were 60 holders of record of our Common Shares, out of which 4 holders of record had a registered address in the United States. These numbers are not representative of the number of beneficial holders of our shares nor is it representative of where such beneficial holders reside, since many of these shares were held of record by brokers or other nominees. The Company is not controlled by another corporation, by any foreign government or by any natural or legal persons except as set forth herein, and there are no arrangements known to the Company which would result in a change in control of the Company as a subsequent date. 135 Selling Shareholders The common shares being offered by the selling shareholders are those previously issued to the selling shareholders, and those issuable to the selling shareholders, upon exercise of the Additional Warrant Shares underlying the January 2024 PIPE Warrants. For additional information regarding the issuances of the January 2024 PIPE Warrants, see “Prospectus Summary – January 2024 Offering” above. We are registering the common shares underlying the Additional Warrant Shares of the January 2024 PIPE Warrants in order to permit the selling shareholders to offer the common shares for resale from time to time. Except for the ownership of common shares and the January 2024 PIPE Warrants, the selling shareholders have not had any material relationship with us within the past three years. The table below lists the selling shareholders and other information regarding the beneficial ownership of the common shares by each of the selling shareholders. The second column lists the number of common shares beneficially owned by each selling shareholder, based on its ownership of the common shares and warrants, as of December 3, 2025, assuming exercise of the Additional Warrant Shares underlying the January 2024 PIPE Warrants held by the selling shareholders on that date, without regard to any limitations on exercises. The third column lists the common shares being offered by this prospectus by the selling shareholders. In accordance with the terms of a registration rights agreement with the selling shareholders, this prospectus generally covers the resale of the Additional Warrant Shares underlying the January 2024 PIPE Warrants, determined as if the outstanding Additional Warrant Shares underlying the January 2024 PIPE Warrants were exercised in full as of the trading day immediately